What it's for (Indications)
- Desferrioxamine mesylate is indicated for the treatment of acute iron intoxication and chronic iron overload.
- For acute iron intoxication, it is primarily used when serum iron levels exceed 350-500 mcg/dL or when clinical signs of severe iron toxicity (e.
- g.
- , shock, severe acidosis, coma) are present.
- In chronic iron overload, the main indication is in patients with transfusion-dependent anemias (e.
- g.
- , thalassemia major, myelodysplastic syndromes, aplastic anemia, sickle cell disease) where iron accumulation from repeated blood transfusions leads to organ damage.
- It is also used in chronic iron overload associated with primary hemochromatosis when phlebotomy is contraindicated or ineffective, and for the management of aluminum overload in dialysis patients when standard treatments prove insufficient.
- The therapeutic objective is to reduce toxic iron or aluminum burdens and mitigate or reverse associated organ damage.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of desferrioxamine mesylate is highly individualized and determined by the patient's iron or aluminum burden, age, body weight, and clinical response to therapy. For acute iron intoxication, it is typically administered via continuous intravenous (IV) infusion, intramuscular (IM) injection, or subcutaneously (SC). Rapid IV administration necessitates careful monitoring due to the risk of sudden hypotension. For chronic iron overload, the most common route is slow subcutaneous infusion via a portable pump over 8-12 hours, typically 5-7 days per week, to maintain consistent drug levels. IV infusion may be utilized during blood transfusions or in patients with inadequate subcutaneous absorption. While oral chelators are increasingly used, desferrioxamine remains critical for severe overload or specific clinical scenarios. Dosing must always be supervised by a physician experienced in iron chelation, with ongoing monitoring of iron parameters, renal and hepatic function, and regular ophthalmic and audiometric assessments. |
Safety & Warnings
Common Side Effects
- Common side effects associated with desferrioxamine mesylate include localized reactions at the injection site (e.
- g.
- , pain, swelling, erythema, pruritus, induration), generalized flushing, hypotension (particularly with rapid IV infusion), gastrointestinal disturbances (e.
- g.
- , nausea, vomiting, abdominal discomfort, diarrhea), headache, and transient blurred vision.
- More serious adverse effects can encompass severe hypersensitivity reactions, including anaphylaxis, renal dysfunction (ranging from acute tubular necrosis to chronic impairment), hepatic dysfunction, and neurological disturbances such as paresthesia or peripheral neuropathy.
- Ocular toxicity, presenting as decreased visual acuity, night blindness, retinal pigmentary changes, or cataracts, and auditory toxicity, including high-frequency hearing loss or deafness, can occur, especially with high doses or prolonged exposure.
- Furthermore, an increased susceptibility to certain bacterial infections, notably *Yersinia enterocolitica* and *Klebsiella pneumoniae*, has been reported.
Serious Warnings
- Black Box Warning: Desferrioxamine mesylate does not carry a formal FDA Black Box Warning. However, healthcare providers and patients must be acutely aware of several serious safety concerns that, while not formally boxed, are critical for safe and effective use, particularly given its role in managing potentially life-threatening iron overload. These serious warnings include the potential for significant **ocular and auditory toxicity**, which can manifest as permanent vision loss or hearing impairment if not promptly detected and managed through dose adjustments. Regular, comprehensive ophthalmologic and audiometric evaluations are therefore considered essential for all patients undergoing chronic desferrioxamine therapy. Furthermore, **renal dysfunction**, ranging from acute tubular necrosis to chronic impairment, can occur, necessitating rigorous monitoring of kidney function throughout treatment. **Acute respiratory distress syndrome (ARDS)** has been reported following rapid, high-dose intravenous infusion, underscoring the critical importance of slow administration rates and close respiratory monitoring in critical care settings. There is an **increased susceptibility to severe infections**, particularly with *Yersinia enterocolitica* and *Klebsiella pneumoniae*, as desferrioxamine can inadvertently act as a growth factor for these bacteria; patients developing fever or any signs of infection during treatment require immediate medical evaluation. Lastly, in pediatric patients, **growth retardation** is a known risk, requiring careful dose titration to balance therapeutic efficacy with potential developmental impacts. These serious adverse effects emphasize the necessity of strict medical supervision and comprehensive patient education throughout the course of desferrioxamine treatment.
- Desferrioxamine mesylate treatment necessitates rigorous monitoring and comprehensive patient education due to several significant potential warnings.
- Patients on chronic therapy must undergo regular ophthalmologic and audiometric examinations to facilitate early detection of ocular and auditory toxicity, which can manifest as reduced visual acuity, night blindness, visual field defects, or high-frequency hearing loss.
- These toxicities are typically dose-dependent and can often be reversible upon appropriate dose reduction or discontinuation.
- Renal and hepatic function must be routinely assessed, as desferrioxamine and its chelated complex are primarily renally excreted, and hepatic impairment can affect drug metabolism.
- Rapid intravenous infusion can precipitate severe hypotension and shock, mandating slow administration rates and meticulous cardiovascular monitoring.
- In pediatric patients, high doses may cause growth retardation, requiring careful dose titration based on iron burden and observed growth parameters.
- An elevated susceptibility to specific bacterial infections, particularly *Yersinia enterocolitica* and *Klebsiella pneumoniae*, is a known risk; patients developing fever or signs of infection should seek immediate medical attention.
How it Works (Mechanism of Action)
Desferrioxamine mesylate functions as a potent iron-chelating agent. Its molecular structure possesses six coordination sites that exhibit a high affinity and specificity for ferric iron (Fe3+). Upon binding, it forms a stable, non-toxic, water-soluble complex known as ferrioxamine. This chelation process effectively mobilizes and sequesters iron from various iron-binding proteins, including transferrin, ferritin, and hemosiderin, while generally sparing essential trace metals such as zinc and copper at therapeutic concentrations. The resulting ferrioxamine complex is subsequently excreted from the body, predominantly via the kidneys into the urine and to a lesser extent through the bile into the feces. By reducing the burden of free and loosely bound iron, desferrioxamine mitigates iron-mediated oxidative tissue damage in vital organs like the heart, liver, and endocrine glands, which is crucial in both acute iron poisoning and chronic iron overload conditions.